AllSight
Companies · ELV · Hospital & Medical Service Plans · Guidance · Sep 10, 2026

Elevance reaffirms 2026 EPS outlook, offering no new upside after Q2 raise

Guidance reaffirmedpriced in
Adjusted EPS at least $27.00, unchanged from the Q2 guidance raise
Elevance Health, Inc. (ELV) — what happened, in plain English, and what it means versus what the market expected.

The filing confirms the existing outlook rather than changing it. Elevance says officers will reaffirm full-year 2026 shareholders’ earnings of at least $20.10 per diluted share, including approximately $6.90 per share of net unfavorable items.

Metric2026 outlookMarket context
Reported shareholders’ earningsAt least $20.10 per diluted shareUnchanged from prior guidance
Net unfavorable itemsApproximately $6.90 per diluted shareIncluded in reported outlook
Adjusted shareholders’ earningsAt least $27.00 per diluted shareSame floor established after Q2

The adjusted-earnings floor remains the key number, and it was already known. The company continues to expect adjusted shareholders’ earnings of at least $27.00 per diluted share. That $27.00 floor was raised with the second-quarter results, so today’s filing preserves the improved outlook but does not add another increase.

Net read: stable, not incremental. The filing reduces concern that the post-Q2 outlook had deteriorated, but it does not constitute a fresh beat or upgrade versus the standing expectation. With no new financial data, new cost assumptions, or higher target, the appropriate scorecard is guidance reaffirmed and the information is effectively priced in.

Read the original 8-K on SEC EDGAR ↗
All ELV filings, decoded →
Related companies in Hospital & Medical Service Plans
Latest across the market
NTSTNETSTREIT debt amendment formalizes investment-grade pricing and widens leverage cushionFLOCFlowco acquisition adds Canadian rod lift but increases debt-funded execution riskCTRECareTrust acquisition adds 45 UK care homes, but SHOP payoff is years awayADCAgree Realty share-count filing adds routine dilution detail, not new business newsACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact